Recommendations on the management of multiple myeloma in 2020

ABSTRACT

With the introduction of immunomodulatory drugs, proteasome inhibitors, and anti-CD38 monoclonal antibodies, major improvements have been achieved in the treatment of multiple myeloma (MM), with a significant impact on the outcome of this disease. Different treatment combinations are now in use and other therapies are being developed. Based on an extensive review of the recent literature, we propose practical recommendations on myeloma management, to be used by hematologists as a reference for daily practice.

KEYWORDS:

• Multiple myeloma
• upfront therapy
• relapse
• novel agents
• transplantation
• immunotherapy
• covid-19

Acknowledgments

MCV wrote the manuscript.

All authors critically reviewed the manuscript and approved the final version.

Disclosure statement

The authors have no conflict of interest to declare.

The authors declared no funding sources in the study design, collection of the data, in the writing of the manuscript and in the decision to submit the manuscript for publication.

Supplementary material

Supplemental data for this article can be accessed here.

Correction Statement

This article has been republished with minor changes. These changes do not impact the academic content of the article.